AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study

Despite being prioritized during initial COVID-19 vaccine rollout, vulnerable individuals at high risk of severe COVID-19 (hospitalization, intensive care unit admission, or death) remain underrepresented in vaccine effectiveness (VE) studies. The RAVEN cohort study (NCT05047822) assessed AZD1222 (ChAdOx1 nCov-19) two-dose primary series VE in vulnerable populations.

Source: Journal of Infection - February 29, 2024 Category: Infectious Diseases Authors: Wilhelmine Meeraus, Mark Joy, Mario Ouwens, Kathryn S Taylor, Sudhir Venkatesan, John Dennis, Trung N. Tran, Ashkan Dashtban, Xuejuan Fan, Robert Williams, Tamsin Morris, Lucy Carty, Debasish Kar, Uy Hoang, Michael Feher, Anna Forbes, Gavin Jamie, William Source Type: research